Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation

J Allergy Clin Immunol. 2019 Sep;144(3):863-866.e5. doi: 10.1016/j.jaci.2019.05.026. Epub 2019 Jun 5.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents / therapeutic use*
  • Autoimmune Diseases / diagnostic imaging
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / genetics
  • Autoimmune Diseases / immunology
  • Azetidines / therapeutic use*
  • Brain / diagnostic imaging
  • Brain Diseases / diagnostic imaging
  • Brain Diseases / drug therapy*
  • Brain Diseases / genetics
  • Brain Diseases / immunology
  • Child
  • Child, Preschool
  • Cytokines / blood
  • Female
  • Humans
  • Infant
  • Janus Kinase 1 / antagonists & inhibitors*
  • Janus Kinase 2 / antagonists & inhibitors*
  • Magnetic Resonance Imaging
  • Male
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use*
  • Purines
  • Pyrazoles
  • Sulfonamides / therapeutic use*
  • Tomography, X-Ray Computed
  • Tumor Necrosis Factor alpha-Induced Protein 3 / genetics*

Substances

  • Anti-Inflammatory Agents
  • Azetidines
  • Cytokines
  • Protein Kinase Inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides
  • JAK1 protein, human
  • JAK2 protein, human
  • Janus Kinase 1
  • Janus Kinase 2
  • TNFAIP3 protein, human
  • Tumor Necrosis Factor alpha-Induced Protein 3
  • baricitinib